Pharmaceutical company Orion Biotechnology Canada Ltd reported on Monday that it received feedback from the Food and Drug Administration (FDA) to facilitate the preparation and submission of the Pre-Investigational New Drug (PIND) application of its lead candidate OB-002O in 2020.
The company added that the PIND was focused on the development of OB-002O as an agent for the treatment of solid tumours. The OB-002 is a chemokine analogue CCR5 antagonist that is being developed in a topical form for HIV prevention (OB-002H) as well as an intravenous immunotherapy agent (OB-002O).
According to the company, CCR5 antagonism has been shown to induce anti-cancer effects in preclinical and Phase 1 clinical studies of colorectal cancer (Halama et al. Cancer Cell 2016) and is an active area of cancer drug development.
In conjunction, the use of OB-002 alone, or in combination with a checkpoint inhibitor, was efficacious in the CT-26 syngeneic colorectal cancer model, which provided the rationale for this Pre-IND submission, concluded the company .
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results